Claims
- 1. A compound having the structural formula ##STR1693## or a nontoxic pharmaceutically acceptable salt thereof, wherein one [DHC]' is a radical of the formula ##STR1694## wherein the dotted line indicates the presence of a double bond in either the 4 or 5 position of the dihydropyridine ring; R.sub.1 is C.sub.1 -C.sub.7 alkyl, C.sub.1 -C.sub.7 haloalkyl or C.sub.7 -C.sub.10 aralkyl; and the carbonyl-containing grouping in formula (a') is attached at the 2, 3 or 4 position of the dihydropyridine ring; and each remaining [DHC]' is H or a radical of formula (a') as defined above.
- 2. A compound according to claim 1, wherein the carbonyl-containing grouping in formula (a') is attached at the 3-position of the dihydropyridine ring.
- 3. A compound according to claim 1, wherein only one [DHC]' is a radical of formula (a') as defined in claim 1.
- 4. A compound according to claim 1, wherein R.sub.1 is CH.sub.3.
- 5. A compound, having the structural formula ##STR1695## wherein one R' is ##STR1696## and each remaining R' is H or ##STR1697##
- 6. A method for site-specifically/sustainedly eliciting an antiviral response in the brain, comprising administering to an animal in need of such treatment a quantity of a compound as defined by claim 1 sufficient to elicit an effective antiviral response in the brain.
- 7. A method according to claim 6, wherein the compound is administered in the form of a pharmaceutically acceptable sustained release composition.
- 8. A method according to claim 6, wherein the compound is administered via a route of administration capable of slowly releasing the compound into the body.
- 9. A pharmaceutical composition, in unit dosage form, for use in eliciting an antiviral response in the brain, said composition comprising:
- (i) an amount of a compound as defined by claim 1 sufficient to elicit an effective antiviral response in the brain; and
- (ii) a non-toxic pharmaceutically acceptable carrier therefor.
- 10. A pharmaceutical composition as claimed in claim 9, said composition being a pharmaceutically acceptable sustained release composition.
- 11. A pharmaceutical composition, in unit dosage form, for use in eliciting an antiviral response in the brain, said composition comprising:
- (i) an amount of a compound as defined by claim 5 sufficient to elicit an effective antiviral response in the brain; and
- (ii) a non-toxic pharmaceutically acceptable carrier therefor.
Priority Claims (1)
Number |
Date |
Country |
Kind |
428192 |
May 1983 |
CAX |
|
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a division of application Ser. No. 07/295,938, filed Jan. 11, 1989, now U.S. Pat. No. 5,008,257; which is a division of application Ser. No. 06/665,940, filed Oct. 29, 1984, now U.S. Pat. No. 4,824,850; which is a continuation-in-part of my earlier applications Ser. No. 06/379,316, filed May 18, 1982, now U.S. Pat. No. 4,479,932; Ser. No. 06/461,543, filed Jan. 27, 1983, abandoned in favor of Ser. No. 06/733,463, filed May 13, 1985, now U.S. Pat. No. 4,727,079; Ser. No. 06/475,493, filed Mar. 15, 1983, now U.S. Pat. No. 4,622,218; and Ser. No. 06/516,382, filed Jul. 22, 1983, now U.S. Pat. No. 4,540,564.
US Referenced Citations (8)
Non-Patent Literature Citations (17)
Entry |
CA 66: 37835q (1967). |
CA 99: 158321j (1983). |
Bodor et al., Science 190, 155-156 (1975). |
Shek et al., J. Med. Chem. 19, 113-117 (1976). |
Bodor et al., in Design of Biopharmaceutical Properties through Products and Analogs, ed. |
Edward B. Roche, American Pharmaceutical Association, Washington, D.C., 98-135 (1977). |
Bodor et al., J. Pharm. Sci. 67, 685-687 (1978). |
Bodor et al., Science 214, 1370-1372 (1981). |
The Friday Evening Post, Health Center Communications, University of Florida, Gainesville, Fla., Aug. 14, 1981. |
Chemical and Engineering News, pp. 24-25, Dec. 21, 1981. |
Science News, vol. 121, #1, p. 7, Jan. 2, 1982. |
Brewster III, Dis. Abst. Int. B., vol. 43 #9, p 2910B (1983). |
Bodor et al., J. Med. Chem. 26, 313-318 (1983). |
Bodor et al., J. Med. Chem. 26, 528-534 (1983). |
Bodor et al., Pharmac. Ther. 19, 337-386 (1983). |
Bodor et al., J. Pharm. Sci. 73, 385-389 (1984). |
Bodor et al., Science 221, 65-67 (1983). |
Divisions (2)
|
Number |
Date |
Country |
Parent |
295938 |
Jan 1989 |
|
Parent |
665940 |
Oct 1984 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
379316 |
May 1982 |
|